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dKey concepts
n Adjuvantation of vaccines is a well-established concept and practice
n Adjuvants enhance and modulate immune responses to antigens. This is particularly important when the antigens
are puriﬁed and lack intrinsic innate and/or adaptive immune triggers
n Adjuvants differ in the types and magnitude of immune responses they elicit, hence they must be selected in view
of the immune response required to induce immunity to a given pathogen or antigen
n Combinations of adjuvants can take advantage of the properties of each individual component of
an adjuvant composition
n Adjuvants are a key tool in developing efﬁcacious vaccines to meet many vaccine challengesAdjuvant concept
The adjuvant concept is more than 80 years old with the ﬁrst
adjuvant present in human vaccines, an aluminium salt (aluminium
potassium sulphate, also known as alum), appearing in the 1920s.
About 70 years later a licensed vaccine with an alternative adjuvant
to aluminium salt was developed (Figure 4.1). The addition of2011 Elsevier B.V.
oi:10.1016/j.pervac.2011.05.004
Open access under CC BY-NC-ND license.
Figure 4.1 Use of adjuvants in vaccines. As with all areas of vaccine development, the availability and variety of adjuvanted vaccines has
increased with a greater understanding of immunology. The antigen approach employed for the individual disease is given in parentheses.
Aluminium salts were the only adjuvant used in licensed vaccine formulations for human vaccines until the 1990s. Several new adjuvants have
been developed and used since.
HPV, human papillomavirus.
90 UNDERSTANDING MODERN VACCINEScomponents other than the pathogen or antigen to vaccine
preparations represents one of the original attempts to improve
vaccine efﬁcacy. Adjuvants are substances that can enhance and
modulate the immunogenicity of the vaccine antigen. In a vaccine,
the speciﬁcity of the immune response is provided by the antigen
and the role of the adjuvant is to amplify this immune response. Live
vaccines usually do not require adjuvants as they mimic natural
infection and are therefore ‘naturally adjuvanted’. Most inactivated
(whole or subunit) vaccines do require adjuvants since the
Adjuvant selection
There is no universal adjuvant to cover all
vaccine needs. The appropriate selection
of adjuvants to match the antigens is key
to the formulation of novel and
efﬁcacious vaccines. For example,
different aluminium salts (phosphate
or hydroxide) are used depending on
the ion charge required for binding to
the antigen.
First use of adjuvants
Adjuvantswere initially developed for use
in animals to increase the yield of serum
antibodies for antitoxins.
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features of the microorganisms that are responsible for triggering
the immune response. Inactivated vaccines may retain some
of the characteristics that stimulate the innate immune system
(ie pathogen-associated molecular patterns [PAMPs], see
Chapter 2 e Vaccine immunology), but the amount and context of
these PAMPs may be insufﬁcient to provoke long-lasting
immunity. Aluminium salts have been sufﬁcient to induce an
adequate immune response for most of the licensed inactivated
and subunit vaccines.
However, many of the modern vaccines consist of highly puriﬁed
antigens for which the natural innate immune triggers are not
present. These reﬁned formulations often show reduced
immunogenicity and therefore require adjuvantation. Classic
aluminium salts are not always capable of eliciting the desired
immune response and more complex adjuvantation may be
required. One of the promising approaches to improve efﬁcacy of
newly developed prophylactic and therapeutic vaccines is the use of
innovative adjuvants including the technique of combining different
types of adjuvants into single formulations.
Aluminium salts
In the 1920s, Gaston Ramon and Alexander Glenny recognised that
several substances added to toxoids had adjuvant properties
(see Chapter 1 e Vaccine evolution). During experimentation with
tetanus and diphtheria toxoids in horses, Ramon observed that the
addition of bread crumbs, tapioca (both starches) or saponin
increased the yields of serum antibodies. In 1926, Glenny
formulated the ﬁrst adjuvanted vaccine by precipitation of diphtheria
antigen onto particles of aluminium potassium sulphate. It was
believed that aluminium compounds enhanced the response to
antigens by extending the time during which antigen is available in
the tissue (the so-called depot effect). It is known today that
aluminium, like many of the new adjuvants described below, acts by
direct activation of the innate immune cells.
Expected beneﬁts
of adjuvants
1. Stronger immune priming:
- Faster immune response
- Elevated immune response
- Broader, cross-protective immunity
against genotypes or drift variants
different from vaccine antigen(s)
- Longer lasting immune response,
fewer boosters needed
2. Enhanced and effective immune
responses in speciﬁc low-responding
populations, such as the elderly or
immunocompromised patients
3. Antigen sparing (use of smaller
amounts of the antigen) e particularly
relevant for pandemic events
4. Acceptable safety proﬁle
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Water-in-oil emulsions as adjuvants were ﬁrst introduced by
Jules Freund in the 1930s. Like aluminium, this adjuvant was
designed to release antigen over an extended time period at the
injection site, acting as an antigen carrier. The emulsion induced
potent immune responses, but the high reactogenicity observed
in humans was unacceptable. It was later established that
the reactogenicity observed was due to impurities present in
the mineral oil, and new formulations lacking impurities were
subsequently developed.The need for innovative adjuvants
As mentioned above, aluminium salts work well for traditional
bacterial toxoids and many of the currently available vaccines
for which antibodies are the main correlate of protection. The
induction of complex, integrated immune responses for diseases
such as human immunodeﬁciency virus (HIV), has reignited
the search for new classes of adjuvants, including improved
water-in-oil emulsions with a less reactogenic proﬁle than Freund’s
original adjuvant.
Table 4.1 shows several adjuvanted vaccines currently available in
Europe and the USA, some of which contain single novel adjuvants
or a combination of adjuvants.Understanding the role of adjuvants
Pathogens contain intrinsic triggers of immune defence, PAMPs,
which are recognised by cells of the innate immune system and
are necessary to elicit a robust immune response (see Chapter 2 e
Vaccine immunology). Some inactivated and subunit vaccines lose
part or most of the pathogen’s intrinsic immunostimulatory ability
due to the inactivation or puriﬁcation processes. These vaccines
therefore require adjuvants in order to enhance an antigen-speciﬁc
adaptive immune response.
TABLE 4.1. EXAMPLES OF ADJUVANTS IN LICENSED VACCINES
Adjuvant Vaccine Product
Aluminium salts DTaP Boostrix, GSK Biologicals
Daptacel, Sanoﬁ Pasteur
Infanrix, GSK Biologicals
Repevax, Sanoﬁ Pasteur
DTaP, polio and Hib Pediacel, Sanoﬁ Pasteur
Pediarix, GSK Biologicals
Pentacel, Sanoﬁ Pasteur
DTwP, Hib and hepatitis B Quinvaxem, Novartis
DTaP, polio, Hib and hepatitis B Infanrix hexa, GSK Biologicals
Hepatitis A Avaxin, Sanoﬁ Pasteur
Havrix, GSK Biologicals
Vaqta, Merck & Co
Hepatitis B Engerix-B, GSK Biologicals
Recombivax HB, Merck & Co
HPV-6/11/16/18 Gardasil, Merck & Co
Inﬂuenza (H5N1) Daronrix, GSK Biologicals
Fluval, Omnivest
Panﬂu, Sinovac
Panvax, CSL Biotherapies
Pneumococcus (conjugated) Prevnar/Prevenar, Wyeth
Synﬂorix, GSK Biologicals
Synthetic MPL (RC-529) Hepatitis B Supervax, Dynavax Technologies
Virosomes Hepatitis A Epaxal, Crucell
Inﬂuenza (seasonal) Inﬂexal, Crucell
Invivac, Solvay
Oil-in-water emulsion (MF59) Inﬂuenza (H1N1) Focetria, Novartis
Inﬂuenza (H5N1) Aﬂunov, Novartis
Inﬂuenza (seasonal) Fluad, Novartis
Montanide ISA51 Cancer CimaVax EGF, Bioven
AS04 Hepatitis B FENDrix, GSK Biologicals
HPV-16/18 Cervarix, GSK Biologicals
Continued on next page
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TABLE 4.1. EXAMPLES OF ADJUVANTS IN LICENSED VACCINESd CONTINUED
Adjuvant Vaccine Product
AS03 Inﬂuenza (H5N1, H1N1) Prepandrix, GSK Biologicals
Pandemrix, GSK Biologicals
Arepanrix, GSK Biologicals
Thermo-reversible oil-in-water emulsion Inﬂuenza (H1N1) Humenza, Sanoﬁ Pasteur
DTaP, paediatric diphtheria, tetanus and acellular pertussis; Hib, Haemophilus inﬂuenza type b; HPV, human papillomavirus, AS04,
Adjuvant System 04; AS03, Adjuvant System 03; DTwP, Hib and hepatitis B, paediatric diphtheria, tetanus and whole cell pertussis; MPL,
monophosphoryl lipid A. The information given in this tab
Possible impact of adjuvants
on immune mechanisms
1. Recognition of PAMPs
2. Presentation of antigens to
T-cell receptor
3. Recognition of co-stimulatory signals
4. Intracellular signalling processes
in APCs
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Sentinel immune cells are equipped with innate receptors, the
so-called pattern recognition receptors (PRRs). These recognise
PAMPs and allow them to distinguish between different broad types
of organism such as bacteria, viruses and parasites (seeChapter 2e
Vaccine immunology).
The stimulation of these receptors and other signals coming from
inﬂammatory processes and/or tissue damage alerts the immune
system and guides it towards the most appropriate type of
response. PRRs include the Toll-like receptors (TLRs) which are, to
date, the best characterised of the PRRs.
A key process in the development of a successful immune
response is the initial encounter with the innate immune system as
this guides the downstream adaptive response. The speciﬁc innate
signals received by antigen-presenting cells (APCs) strongly
inﬂuence the magnitude and quality of the ensuing T- and
B-lymphocyte responses, the nature of T-cell response, and the
induction of memory cells (see Chapter 2 e Vaccine immunology).
The innate and adaptive parts of the immune system need to
communicate with each other in order to induce the relevant
immune response. Dendritic cells (DCs), macrophages and
monocytes participate in the presentation of antigens to the cellular
mediators of immune memory, the T cells, which, in turn, promote
the activation and maturation of speciﬁc antibody-producing B cells.
le is not meant to be exhaustive but to give an overview of the subject matter.
The role of adjuvants in vaccines
Adjuvantsmimicnaturaldefensive trigger
molecules in order to stimulate a strong
and comprehensive immune response to
the antigen. These triggers may be
immuno-enhancers, including exogenous
or synthetic microbial derivatives, or
endogenous immuno-active compounds
such as cytokines, chemokines and
co-stimulatory molecules, or other
natural compounds such as saponins,
squalene or vitamin E.
Main immunemechanisms that
can be impacted by adjuvants
Adjuvants help to make an antigen more
visible or reactive to the immune system
and several different mechanisms of
action have been proposed depending on
the adjuvant.
‘Persistence of antigen’ was considered
VACCINE ADJUVANTS 95They are the link between the innate and adaptive immune
response. Based on its nature, an adjuvant can enhance the
adaptive immune response to vaccine antigens by amplifying or
modulating any of the signals involved in the process of innate
immune response activation.
ADJUVANTSMIMIC NATURAL IMMUNE-DEFENCE TRIGGERS
The discovery of PRRs, PAMPs and TLRs, and the recognition of the
link between innate and adaptive immunity, has facilitated the
development of a series of innovative adjuvants. The main immune
mechanisms that can be impacted by adjuvants are summarised in
the box on the right. Their general mode of action based on current
evidence is shown in Figure 4.2. In general, adjuvants act in
a similar way to the immune-defence triggers present in pathogens
by interacting with APCs and promoting appropriate immune
responses. Based on the different PRRs identiﬁed and their
associated ligands and downstream effects (see Appendices,
Supplementary Table 1), one area of research on new adjuvants is
the identiﬁcation of substances able to mimic the effect of one or
more natural ligands, eg TLR agonists.previously to be the result of a simple
depot effect. Today, this phenomenon is
believed to include features such as
Adjuvants in licensed vaccinesimproved antigen delivery and enhanced
uptake by APCs.
Direct activation of innate immune cells,
including APCs, induces the localised
release of cytokines and chemokines,
through speciﬁc receptors (such as
TLRs), and inﬂuences the subsequent
adaptive immune response.
Better immune targetingmay be achieved
by inﬂuencing the type of adaptive
immune response induced through an
enhanced recruitment and stimulation of
APCs at the site of injection and in the
regional lymph nodes.ALUMINIUM SALTS
Different aluminium salts are contained in numerous licensed
vaccines (Table 4.2). Aluminium salt adjuvants have complex,
heterogeneous physical structures and the antigen is adsorbed to
the adjuvant through hydrophobic and electrostatic interactions
between antigen and the aluminium salt. Aluminium hydroxide is
positively charged at a physiological pH of 7.4 and binds acidic
proteins. Aluminium phosphate, on the other hand, is negatively
charged and therefore binds basic proteins.
Depending on the hydrophobic interactions with the antigen,
the appropriate aluminium salt is selected to maintain antigen
immunogenicity and to obtain maximum adjuvant effect (Table 4.2).
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Figure 4.2 Adjuvants: general mode of
action based on current evidence.
Adjuvants mimic elements from pathogens
that are recognised by the innate immune
system (1). This results in a local cytokine
response and recruitment of various innate
cells including monocytes and immature
DCs (2). Immature innate cells integrate
these proinﬂammatory signals and begin to
mature in APCs. Simultaneously, they
migrate to the local draining lymph nodes
where they induce T- and B-cell
responses (3). This leads to the production
of adaptive immune effectors such as CD4þ
T cells and antibodies (4). Adjuvants can
therefore inﬂuence the magnitude and
quality of the adaptive immune response via
effects on the innate response.
Compared with the same antigen in a
non-adjuvanted formulation, the expected
beneﬁts of adjuvants are:
l An increased recruitment of innate cells at
the site of injection
l An increased number of activated APCs
migrating to the draining lymph node
l An increased uptake of the antigen by
APCs with a subsequent enhancement
and modulation of the adaptive
immune response
The immune proﬁle of the adaptive immune
response is therefore inﬂuenced by
adjuvants and may result in an improved
cytokine pattern in quantity and quality,
a greater diversity of CD4þ T cells, and
a wider antibody proﬁle.
DC, dendritic cell; APC, antigen-presenting
cell; CD, cluster of differentiation.
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TABLE 4.2. EXAMPLES OF VACCINES
ADJUVANTED WITH ALUMINIUM SALTS
Aluminium salt Vaccine
Al(OH)3 e aluminium hydroxide and/or
AlPO4 e aluminium phosphate
Pertussis
Diphtheria
Tetanus
HBV
HAV
(Al)2PO4SO4OH e aluminium
hydroxyphosphate sulphate
HPV
HBV, hepatitis B virus; HAV, hepatitis A virus;
HPV, human papillomavirus.
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because they promote antigen persistence and prolong release of
the antigen. It has also been suggested that the antigens adsorbed
on the aluminium salts are presented in a particulatemultivalent form,
making them more efﬁciently internalised by APCs. Recent studies
have shown that this is not always the case. Most antigens are rapidly
desorbed from aluminium salts following exposure to interstitial ﬂuid,
therefore adsorption is not always required to achieve adjuvanticity.
However, adsorption or entrapment in aggregates might favour
a high local antigen concentration and improved uptake by APCs. In
addition, insoluble aluminium salts have been shown to directly
activate innate immune cells. It has been suggested that the effect of
aluminium salts on cells may lead to the production of uric acid in vivo
from the breakdown of purine nucleotides in apoptotic cells, which
act as damage-associated molecular patterns (DAMPs). DAMPs are
generally substances released by stressed or dying cells and are
recognised by cells of the innate immune system.
Aluminium salts have recently been shown to activate in vitro
components of the ‘inﬂammasome’ complex, but whether the
activation of this pathway is required for the adjuvant effect
of aluminium salts in vivo is uncertain. Nevertheless, new data
also clearly show that aluminium salts have additional effects e
beyond promoting persistence of antigen e that account for their
adjuvant properties.Limitation of aluminium salts
As discussed previously, aluminium salts have been used
successfully in vaccines against pathogens where antibodies
provided the primarymechanism of protection. Aluminium salts exert
little effect on Th1-type or cytotoxic T-cell responses, which are
required for responses against intracellular pathogens. Hence, with
vaccines for such pathogens, aluminium salt adjuvants have been
found to be inadequate. For example, all attempts to develop
a malaria vaccine formulated with aluminium salt as adjuvant have
failed so far.
Figure 4.3 Structure of a liposome. Liposomes consist of
phospholipids, molecules with hydrophilic heads and
hydrophobic tails. After dispersion in water, groups of
phospholipids form small spheres which enclose an
aqueous core.
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Liposomes are artiﬁcial vesicles consisting of lipid layers that can
encapsulate/intercalate antigens in their membrane and act as
antigen-delivery vehicles (Figure 4.3). Some licensed products
contain virosomese spherical lipid vesicles that include the functional
viral glycoproteins haemagglutinin (HA) and neuraminidase (NA) from
inﬂuenza. These glycoproteins are thought to facilitate antigen uptake
by APCs (Figure 4.4).
The suggested mechanism of action of inﬂuenza-based virosomes
involves direct interaction of virosome particles with APCs or, in
some cases, with B cells which, in turn, activate T cells. The
inﬂuenza HA antigen targets the virosomes to APCs which engulf it
by endocytosis and present the antigens to T cells after proteolytic
Figure 4.4 Structure of a virosome. Virosome
technology uses liposome-based structures that have
viral proteins embedded into the membrane, for example
the haemagglutinin and neuraminidase proteins of an
inﬂuenza virus. These elements help to target the
virosome to the immune system cells, delivering the
vaccine antigen.
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another important determinant for the immunostimulating effect of
virosomes. Currently there are two virosome-adjuvanted vaccines,
licensed in some European and non-European countries (Table 4.1).EMULSIONS
Emulsions are based on the combination of two immiscible
components, typically an oil and water, with one substance
dispersed into the other (Figure 4.5).
Figure 4.5 Emulsions in vaccines. Emulsions consist of
two or more immiscible liquids such as water and oil.
The minor component (the dispersed phase) is dispersed
in the predominant component (the continuous phase).
Emulsions are stabilised with amphiphilic molecules,
referred to as emulsiﬁers or surfactants. Depending on the
volume fractions and the emulsiﬁer, either an oil-in-water
(A) or a water-in-oil (B) emulsion is generated.
Courtesy of GSK Biologicals (A). Courtesy of Professor Daniel E Resasco,
University of Oklahoma, USA (B).
100 UNDERSTANDING MODERN VACCINESBecause of this inherent incompatibility, emulsions need to
be stabilised by the addition of surfactants or an emulsiﬁer,
eg substances like Tween 80 or Span 85. Two different types of
emulsions have been developed: water-in-oil and oil-in-water. Both
types of emulsion induce high antibody responses, but oil-in-water
emulsions tend to have better reactogenicity proﬁles. Oil-in-water
emulsionshavebeenusedsuccessfully in licensedvaccines (Table4.1).
Most oil-in-water emulsions are based on squalene, an organic
compound which occurs naturally in all plants and animals,
including humans. Squalene is the precursor for the biosynthesis of
several steroid hormones, vitamin D and cholesterol. In humans, the
highest amount of squalene is found in the sebaceous glands, from
which the average secretion is 475 mg squalene per day. Squalene
VACCINE ADJUVANTS 101is used as a skin moisturiser and antioxidant in cosmetics. For
pharmaceutical products, squalene is derived from shark liver
as this is the purest source available. Importantly, the adjuvant
effect of squalene is only observed when the molecule is part of an
oil-in-water emulsion.MF59
MF59 is an oil-in-water emulsion made of squalene droplets in
a continuous aqueous phase, with a diameter of 167  20 nm
(Figure 4.6). MF59 induces recruitment and activation of APCs
leading to inﬂammatory responses. The emulsion acts moreFigure 4.6 Structure of MF59. MF59 is an oil-in-water
emulsion containing squalene as the dispersed phase
and two non-ionic surfactants, Tween 80 and Span 85.
Squalene is a triterpene hydrocarbon found naturally in
various plants and in the organs and tissues of many
animals, including humans.
102 UNDERSTANDING MODERN VACCINESspeciﬁcally on macrophages present at the site of injection. A
local increase of chemokine release (see Chapter 2 e Vaccine
immunology) inﬂuences the recruitment of immune cells from the
blood to the site of vaccination, creating an ampliﬁcation loop.
MF59 also increases antigen uptake by monocytes and enhances
differentiation towards a mature phenotype, thereby promoting
migration of antigen-loaded cells to the draining lymph node.
Compared with aluminium salts, a stronger immune response,
eg higher antibody and T-cell response, is elicited (Seubert
et al., 2008).
MF59 is present in licensed seasonal and pandemic inﬂuenza
vaccines (Table 4.1). It enhances immune responses in the elderly
population and can facilitate immune responses against speciﬁc
drift variants of the seasonal inﬂuenza virus not included in the
vaccine. MF59 demonstrated how an adjuvant can improve the
immune response to a classical vaccine in a challenging population,
such as the elderly, which is affected by immune senescence
(Podda, 2001). Clinical studies with an MF59-adjuvanted
pandemic inﬂuenza vaccine showed antigen-sparing abilities, and
for the H5N1 vaccine, the induction of some cross-reactivity
versus different viral clades (Banzhoff et al., 2009). The induction
of cross-reactive immunity against drifted strains may be very
important during a pandemic, as it is very likely that the emerging
virus will continue to mutate as the pandemic proceeds.Thermo-reversible emulsion adjuvant
A thermo-reversible oil-in-water emulsion containing squalene,
emulsiﬁed with surfactants, is present in the formulation of an H1N1
pandemic inﬂuenza vaccine which was licensed in Europe in 2010
(Table 4.1). The mechanism of action has not yet been reported.ADJUVANT COMBINATIONS IN LICENSED VACCINES
Well-known adjuvants, such as aluminium salts, oil-in-water
emulsions or liposomes, are combined with other compounds
which act as immuno-enhancers to better modulate and guide
VACCINE ADJUVANTS 103speciﬁc components of the immune system aiming to achieve the
desired immune response. The more complex formulations,
comprising three or more adjuvant components, are designed in
particular to induce more potent cellular immune responses (see
Chapter 2 e Vaccine immunology).
AS04
The ﬁrst example of a combination of adjuvants is the Adjuvant
System (AS) 04 (AS04), which is based on a lipopolysaccharide
(LPS) derivative, monophosphoryl lipid A (MPL) and aluminium
salts (Figure 4.7). LPS, derived from Gram-negative bacteria, is
a potent immunostimulant and a speciﬁc TLR4 agonist. MPL is
obtained by mild hydrolysis and further puriﬁcation of LPS
derived from Salmonella minnesota. The product has similar
immunostimulatory properties to LPS, but lacks the reactogenicity
of native LPS. In AS04, MPL is adsorbed onto aluminium hydroxide
or aluminium phosphate, depending on the vaccine with which
it is used.
In AS04, MPL plays a crucial role in the activation of the innate
immune system. Direct stimulation of TLR4 leads to the maturation
of APCs, inducing the expression of cytokines that in turn enhance
the adaptive immune response by stimulating the maturation of
Th cells, in particular Th1. Therefore, recognition of MPL by TLR4
leads to enhanced humoral and cellular immune responses. AS04
has to be administered at the same injection site as the antigen e
together or within 24 h e to exert its effect. During this period,
AS04 transiently induces local innate cell activation and cytokine
production, as demonstrated by the local increase in activated
antigen-loaded DCs and monocytes, which migrate to the lymph
node draining the injection site. Aluminium salt appears to
modulate and prolong the cytokine responses to MPL at the
injection site. Taken together, these results support a model where
the addition of MPL to aluminium salt enhances the vaccine
response by prompting increased activation of APCs and
downstream enhanced stimulation of Th1 T-cell responses
(Didierlaurent et al., 2009).
Figure 4.7 Chemical structure of LPS and MPL. LPS is found in
the membranes of Gram-negative bacteria and is an important
recognition pattern for the innate immune response. TLR4
agonist MPL is a derivative of LPS that mimics natural defence
triggers produced by a pathogen, but with greatly reduced
reactogenicity. During the puriﬁcation process parts of the sugar
backbone, one phosphate functionality and two side chains are
cleaved from LPS. A synthetic MPL analogue (RC-529) has also
been developed and is used in an HBV vaccine (Table 4.1). The
RC-529 molecule features a monosaccharide derivative instead
of the hexa-acylated disaccharide chain in MPL.
LPS, lipopolysaccharide; MPL, monophosphoryl lipid A; TLR, Toll-like
receptor; HBV, hepatitis B virus.
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VACCINE ADJUVANTS 105AS04 is currently used in two licensed vaccines (Table 4.1). The ﬁrst
licensed vaccine adjuvanted with AS04 was a hepatitis B virus
(HBV) vaccine for pre-haemodialysis and haemodialysis patients,
who are relatively poor responders to aluminium-adjuvanted HBV
vaccine. In this target population, the vaccine formulation
adjuvanted with AS04 signiﬁcantly enhances the immune response
to hepatitis B antigen and induces more rapid, higher and longer
lasting seroprotection and enhanced cell-mediated immunity (CMI)
compared with the aluminium-adjuvanted vaccine (Kong et al.,
2005). Similarly, the AS04-adjuvanted human papillomavirus (HPV)
vaccine has shown the ability to induce higher antibody levels
when compared with the same antigen formulated with aluminium
salts (see case study 1, Chapter 5 e Vaccine development).
Furthermore, the AS04-adjuvanted HPV vaccine provides
cross-protection against certain other high-risk HPV types not
contained in the vaccine (Paavonen et al., 2009).
AS03
AS03 (Figure 4.8) is a combination of adjuvants, based on
a-tocopherol (vitamin E) and squalene in an oil-in-water emulsion
with a droplet diameter of 150e155 nm. It is used in pandemic
inﬂuenza vaccines (Table 4.1). Vitamin E is a lipid-soluble antioxidant
with immune-enhancing properties which is present in the human
body in muscles, adipose tissues, the adrenal and pituitary glands,
and pancreas. The most important function of vitamin E is to
maintain the integrity of cellular membranes by protecting their
physical stability, and by inhibiting tissue damage caused by
oxidation. Vitamin E is exclusively synthesised in plants and found in
high amounts in vegetable oils and nuts. Vitamin E is widely used in
cosmetics and in foods as a dietary supplement. The vitamin E used
in vaccines is of synthetic origin.
Both monocytes and macrophages respond to AS03 with a local
production of a range of cytokines and chemokines. Macrophages
are the most likely initiators of the cytokine response, whereas
recruited monocytes elicit a second wave of chemokine secretion
and further innate cell recruitment (Morel et al., 2011).
Figure 4.8 Structure of AS03. AS03 contains a-tocopherol (vitamin E) and squalene in an oil-in-water emulsion, stabilised by the surfactant
Tween 80. a-tocopherol is the preferentially absorbed form of vitamin E in humans and modulates innate cytokine production, enhancing cell
recruitment and antigen uptake. Vitamin E has immunostimulatory properties.
106 UNDERSTANDING MODERN VACCINESAn AS03-adjuvanted pandemic inﬂuenza vaccine (Table 4.1) has
been shown to allow for antigen sparing, ie less antigen is needed
per vaccine dose (Leroux-Roels et al., 2007; Roman et al., 2010).
Also a high level of cross-reactive immunity to heterologous strains
of H5N1 has been observed (Leroux-Roels et al., 2008).
Other adjuvants in late-stage (Phase III)
development
There are currently several newly developed adjuvants being
evaluated in Phase III clinical studies. Adjuvants in earlier
development phases are described in Chapter 6 e Vaccines of
the future.
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Novel water-in-oil emulsions have recently been developed for
use in both therapeutic and prophylactic vaccines. Montanide
ISA51 is a water-in-oil emulsion containing mineral oil and
mannide-mono-oleate as an emulsiﬁer. These emulsions are used
as adjuvants with epidermal growth factor (EGF) as antigen in
ongoing Phase III studies against cancer. Montanide adjuvants
induce a strong immune response with an improved safety proﬁle
compared with Freund’s water-in-oil emulsion, but mild-to-severe
local reactions are still observed in about half of the subjects in
clinical trials. For this reason the Montanide adjuvants are
applied mainly in immunotherapy. A non-small-cell lung cancer
(NSCLC) vaccine containing Montanide ISA51 as an adjuvant
was recently registered in Cuba and Chile.
MICROBIAL DNA IMMUNOSTIMULATORY SEQUENCES
Microbial DNA contains intrinsic immunostimulatory sequences
(ISS) which act as ligands of intracellular TLRs, such as TLR9. When
recognised by TLRs, ISS can lead to ampliﬁcation of the adaptive
immune response, in particular cell-mediated immunity. Several ISS
with distinct biological activities have been characterised and
preliminary clinical data show that the use of these sequences in
vaccines can enhance humoral and cellular immune responses to
the vaccine antigens.
One example of an ISS is CpG 7909 (Figure 4.9), an agonist of TLR9
and an inducer of proinﬂammatory cytokines. CpG refers to a group
of synthetic oligodeoxynucleotides derived from bacterial DNA
containing unmethylated CpG motifs. CpG 7909 stimulates TLR9,
induces Th1 immunity and cytotoxic T-lymphocyte responses in
animals, and is currently in Phase III clinical trials as part of an
adjuvanted HBV vaccine (Cooper et al., 2004).
AS01
AS01 combines the effects of three components: liposome, MPL
(TLR4 agonist) and QS21. QS21 is a triterpene glycoside derived
from a saponin extracted from the bark of the South American tree
Figure 4.9 Structureof an immunostimulatory sequence. One example of an immunostimulatory sequence isCpG7909.CpG-richDNA is anagonist
of TLR9andan inducer of proinﬂammatory cytokines. CpG-rich regions are characterisedbymultiple occurrencesof adjacent cytosine (C) andguanine
(G) residues in a linear sequence (the p indicates that C and G are connected by a phosphodiester bond). CpG regions are observed at a lower
frequency than would be predicted by random nucleotide distribution in the DNA of vertebrates, which is in contrast with the DNA of microorganisms.
CpG, adjacent cytosine (C) and guanine (G) residues in a linear sequence connected by a phosphodiester bond; TLR, Toll-like receptor.
108 UNDERSTANDING MODERN VACCINESQuillaja saponaria (Figure 4.10). Saponins are used widely as
emulsiﬁers in cosmetics as well as in the food and drink industry. The
crude extract, known as Quil A, was ﬁrst limited to use as an adjuvant
for veterinary vaccines due to its local reactogenicity. The puriﬁed
QS21 fraction derived from Quil A has potent ability to enhance
Figure 4.10 Chemical structure of QS21. QS21 is
a triterpene glycoside derivative of a saponin which is
extracted from the bark of the South American tree Quillaja
saponaria. Saponins are included in many cosmetic and
industrial products.
VACCINE ADJUVANTS 109antigen presentation to APCs, especially to induce cytotoxic
T-lymphocyte production when tested in animals (Newman et al.,
1997). It has been shown that QS21 as a surfactant can be used to
facilitate penetration of proteins through cell membranes, thus
inducing intracellular immune responses. QS21 has shown an
acceptable tolerability proﬁle for use in human candidate vaccines
when properly formulated with ISCOM (immune-stimulating
complex consisting of cholesterol and phospholipids), or liposomes.
Several clinical trials are in progress with AS01-containing candidate
vaccines against infections, including HIV, tuberculosis and malaria.
The active substance in the candidate malaria vaccine, currently in
Phase III, is the recombinant antigen RTS,S which targets the
pre-erythrocytic stage of the parasite (see Chapter 3 e Vaccine
antigens). Protective immunity against malaria requires the speciﬁc
stimulation of both humoral and CMI responses, with the goal of
decreasing the number of infectious parasites available to invade
the liver while also destroying any hepatocytes that become
infected. The RTS,S vaccine antigen has been formulated with
110 UNDERSTANDING MODERN VACCINESseveral different adjuvant combinations (Kester et al., 2009). AS01
has been selected for the ﬁnal formulation because it demonstrated
a better immune response and showed a trend towards improved
efﬁcacy in several clinical trials compared with the other
adjuvant combinations.
AS15 FOR ANTIGEN-SPECIFIC CANCER
IMMUNOTHERAPEUTICS
AS15 combines the effects of four adjuvants: liposome, MPL
(TLR4 agonist), CpG (TLR9 agonist) and QS21. AS15, the most
complex combination of adjuvants to date, is under investigation
for use in cancer immunotherapy (Brichard and Lejeune, 2007).
Antigen-speciﬁc cancer immunotherapeutics (ASCI) are designed
to treat cancer by targeting antigens that are selectively
expressed or over-expressed by tumour cells, but not by normal
cells. AS15 has been selected for use in ASCI based on its ability
to induce both high antibody titres and robust T-cell responses.
AS15 aims to improve the immune response against the target
antigen through a stronger immune activation which is sufﬁcient
to overcome tumour immuno-suppressive processes. It has been
shown in clinical trials that AS15, in comparison with other
adjuvant combinations, elicits the most appropriate immune
response for ASCI. The melanoma antigen A3 (MAGE-A3) is the
target of current ASCI applications since it is expressed by
different tumours. After showing promising results in Phase II
studies, MAGE-A3/AS15 is in Phase III clinical studies as
cancer-speciﬁc immunotherapy against NSCLC and melanoma.
Safety proﬁle of adjuvants
The safety proﬁle of aluminium salt adjuvants has been
well established through the use of billions of doses of
aluminium-containing vaccines administered to infants, children,
adolescents, adults and the elderly over more than 80 years.
The safety of MF59 and virosomes has been demonstrated
through almost a decade of use. Innovative adjuvants to date
have shown an acceptable safety proﬁle in clinical trials across a
How adjuvants can help to
address vaccination challenges
Complex diseases
- AS01-adjuvanted RTS,S candidate
malaria vaccine: immune response
including strong humoral and T-cell
responses together with clinical
efﬁcacy represents the ﬁrst evidence
that a vaccine against a parasite
is feasible
- MF59- and AS03-adjuvanted pandemic
inﬂuenza vaccines: antigen-sparing
effect and cross-immunity observed
for H5N1
Speciﬁc populations
- AS04-adjuvanted HBV vaccine:
enhanced immune response in pre-
haemodialysis and haemodialysis
immunocompromised patients
- MF59-adjuvanted seasonal inﬂuenza
vaccine: enhanced immune response in
elderly/immunosenescent subjects
VACCINE ADJUVANTS 111variety of applications and in post-licensure experience. Increased
reactogenicity, especially at the injection site, is consistently found
for adjuvanted vaccines compared with those that are
non-adjuvanted. The vaccination-related local symptoms which
are generally reported with higher frequency are mild to moderate
in intensity, of short duration, and do not impact compliance
with vaccination schedules. Overall, adjuvanted vaccines are
considered to have a positive beneﬁterisk ratio that is clinically
acceptable. For more detailed information on vaccine safety see
Chapter 5 e Vaccine development.
Conclusion
More in-depth understanding and recognition of the important role
of the innate immune response in regulating the induction of an
adaptive response has led to a reappraisal of the role that adjuvants
can play in vaccinology and is enabling vaccine researchers to use
adjuvants to greater advantage.
Development of novel adjuvants and adjuvant combinations is likely
to help to address the challenges in modern vaccinology, such as
vaccines targeting complex pathogens (see Chapter 3 e Vaccine
antigens) or vaccines for immunologically challenged subjects. In
addition to their role in prophylactic vaccines, current and future
adjuvants are likely to play a prominent role as immunotherapeutics,
especially for cancer therapy.
The box, right, summarises the challenges of complex diseases
and the needs of speciﬁc populations and how adjuvants can help
to address them.
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